Immune-Mediated Coronary Stent Failure: From PCI-Induced Vascular Injury to In-Stent Restenosis, Neoatherosclerosis and Stent Thrombosis
Authors:
- Sotiris KyriakouSotiris Kyriakou
- Argyris KyriakouAKArgyris Kyriakou
- Marilina NeokleousMNMarilina Neokleous
- Eren Ozan BakırEBEren Ozan Bakır
- Petros AgathangelouPAPetros Agathangelou
- Filippos TriposkiadisFTFilippos Triposkiadis
- Gönül ZerenGZGönül Zeren
- Panos GeorghiouPGPanos Georghiou
- Georgios P. GeorghiouGeorgios P. Georghiou
Open Access
Abstract
Percutaneous coronary intervention (PCI) treats focal coronary obstruction by compressing plaque, injuring the vessel wall, and placing a metallic or bioresorbable scaffold. Most treated segments heal, but a small minority enter a prolonged, excessive, or unstable repair state that contributes to in-stent restenosis (ISR), in-stent neoatherosclerosis, and stent thrombosis (ST). Human evidence is strongest for delayed healing, uncovered struts, macrophage-rich neoatherosclerosis, and hypersensitivity-associated late thrombosis, whereas routine immune biomarker-guided care remains unsupported. The practical question addressed here is therefore not whether inflammation participates, which is established, but which immune signals, read together with intravascular imaging, could realistically change post-PCI management. The narrowed lumen is only the visible endpoint; beneath it sits vascular repair shaped by device-material exposure, local haemodynamics, and host immunity. Endothelial denudation and platelet activation initiate fibrin deposition, complement signalling, and release of damage-associated molecular patterns (DAMPs). Neutrophils, monocytes, and macrophages dominate early, followed by lymphocytes and vascular smooth muscle cells that remodel the repair compartment. Drug-eluting stents (DES) have markedly reduced early neointimal hyperplasia, yet selected late failures still involve delayed endothelial recovery, chronic peristrut inflammation, hypersensitivity, and neoatherosclerotic transformation. Immune biology is useful at the bedside only when interpreted with procedural context, device design, and patient phenotype. Imaging-defined endpoints and paired immune phenotyping are therefore needed to guide treatment by mechanism instead of angiography or isolated biomarkers.Keywords
All Related Versions
This publication has 67 references indexed in Scilit:
- TET2-Driven Clonal Hematopoiesis and Response to CanakinumabJAMA Cardiology, 2022
- A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol: part 2—intra-arterial administrationEuropean Radiology, 2022
- Restenosis, Stent Thrombosis, and Bleeding ComplicationsJACC, 2018
- Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic PatientsJACC, 2013
- In-Stent NeoatherosclerosisJACC, 2012
- Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography StudiesJACC, 2012
- The Pathology of Neoatherosclerosis in Human Coronary ImplantsJACC, 2011
- Coronary Responses and Differential Mechanisms of Late Stent Thrombosis Attributed to First-Generation Sirolimus- and Paclitaxel-Eluting StentsJACC, 2011
- Pathology of Drug-Eluting Stents in HumansJACC, 2006
- Hypersensitivity Cases Associated With Drug-Eluting Coronary StentsJACC, 2006